ClinicalTrials.gg
CompletedNCT00077857Updated May 10, 2013Results posted

A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

A Phase 2 interventional study of capecitabine (Xeloda®) and docetaxel (Taxotere®) in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 94 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-10.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
23rd of 227
470 · median 54
Started
2003
with 13 others
Phase 2
121 of 233
20 open now
Registered
16th of 233
by date
Lead sponsor
12 of 233
Hoffmann-La Roche

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 23rd largest by enrollment of the 227 interventional ones that give a count, is one of 14 that started in 2003, is one of 121 in phase 2, and was the 16th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This 2 arm study compared the efficacy and safety of label dose of capecitabine (Xeloda®) to that of a lower dose of Xeloda® plus docetaxel (Taxotere®) in patients with locally advanced or metastatic breast cancer after failure of chemotherapy with an anthracycline. Patients were randomized to receive either 1250 mg/m\^2 or 825 mg/m\^2 orally twice a day (po bid) on days 1-14 of each 3 week cycle, in combination with Taxotere® 75 mg/m2 intravenous (iv) on day 1 of each 3 week cycle. The anticipated time on study treatment was until disease progression and the target sample size was 440 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women >=18 years of age;
  • >=1 target lesion;
  • locally advanced or breast cancer;
  • demonstrated resistance to anthracycline;
  • >=2 regimens of chemotherapy for advanced/metastatic disease.

Exclusion criteria

Exclusion Criteria:

  • previous treatment with Xeloda, continuous 5-fluorouracil infusion, or other oral fluoropyrimidines;
  • previous treatment with paclitaxel or docetaxel for advanced/ disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
470 participants (actual)

Study arms

  • Experimental
    1250 mg/m^2 capecitabine + docetaxel

    1250 mg/m\^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m\^2 intravenous on day 1 of each 3 week cycle.

    Drug: capecitabine (Xeloda®) · Drug: docetaxel (Taxotere®)

  • Experimental
    825 mg/m^2 capecitabine + docetaxel

    825 mg/m\^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m\^2 intravenous on day 1 of each 3 week cycle.

    Drug: capecitabine (Xeloda®) · Drug: docetaxel (Taxotere®)

Interventions

  • 825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.

    Also known as: Xeloda®

  • 75 mg/m\^2 intravenous on day 1 of each 3 week cycle

    Also known as: Taxotere®

06

What researchers measure

Primary outcomes

  1. Time to Progression of Disease or Death

    Progression Free Survival was defined as the time from the date of randomization to the day of documented disease progression or death due to any cause.

    Time frame: Event driven (after 350 events). Median observation time was approximately 16 months.

Secondary outcomes

  1. Percentage of Participants With Best Overall Response Being Complete Response (CR) or Partial Response (PR)

    According to Response Evaluation Criteria in Solid Tumors (RECIST) criteria: CR is defined as the disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the nadir sum LD.

    Time frame: Until Progressive Disease (PD) or end of primary study treatment (up to 16 cycles) plus 28 days.

  2. Time to Overall Response

    For patients with Best Overall Response being Complete Response (CR) or Partial Response (PR), time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR were met. The percentage of participants with overall response within the given time ranges in each of the categories: Weeks 1-6, 7-12, 13-18, 19-24, 25-30, 31-36, and 43-48 are reported.

    Time frame: Until PD or end of primary study treatment (up to 16 cycles) plus 28 days.

  3. Duration of Overall Response

    Duration of overall response was measured from the time that measurement criteria were first met for Complete Response or Partial Response until the first date that progressive disease or death was documented.

    Time frame: Until PD or death. Median duration of response was approximately 7 months.

  4. Time to Treatment Failure

    The time to treatment failure was the time from the date of randomization to the first occurrence of any of the following events: * adverse events * insufficient therapeutic response (disease progression) * death * failure to return * refusing treatment/being unwilling to cooperate * withdrawing consent.

    Time frame: Until premature withdrawal or end of primary study treatment (up to 16 cycles).

  5. Overall Survival

    Overall Survival was measured as the time from the date of randomization to the date of death.

    Time frame: Throughout the study. Median observation time was approximately 16 months.

  6. Number of Participants With Adverse Events and Serious Adverse Events

    An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is Life-Threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Additional information about Adverse Events can be found in the Adverse Event Section.

    Time frame: First study drug intake until last study drug intake plus 28 days

07

Results

Posted May 10, 2013

Participant flow

Participant flow — Overall Study
Milestone1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Started235235
Received study drug231234
Safety population: actual dose received217248
Completed3431
Not completed201204
Withdrew: Adverse event3032
Withdrew: Death73
Withdrew: Insufficient therapeutic response112128
Withdrew: Violation of selection criteria at entry31
Withdrew: Other protocol violation01
Withdrew: Refused treatment2921
Withdrew: Failure to return55
Withdrew: Other1513

Outcome measures

PrimaryTime to Progression of Disease or Death

Progression Free Survival was defined as the time from the date of randomization to the day of documented disease progression or death due to any cause.

Time frame:
Event driven (after 350 events). Median observation time was approximately 16 months.
Reported as:
Median · Months
Time to Progression of Disease or Death
Months1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Time to Progression of Disease or Death7.9 (6.9 to 8.5)5.8 (4.9 to 7.1)
SecondaryPercentage of Participants With Best Overall Response Being Complete Response (CR) or Partial Response (PR)

According to Response Evaluation Criteria in Solid Tumors (RECIST) criteria: CR is defined as the disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the nadir sum LD.

Time frame:
Until Progressive Disease (PD) or end of primary study treatment (up to 16 cycles) plus 28 days.
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Overall Response Being Complete Response (CR) or Partial Response (PR)
Percentage of participants1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Percentage of Participants With Best Overall Response Being Complete Response (CR) or Partial Response (PR)45.1 (38.6 to 51.7)37.4 (31.2 to 44.0)
SecondaryTime to Overall Response

For patients with Best Overall Response being Complete Response (CR) or Partial Response (PR), time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR were met. The percentage of participants with overall response within the given time ranges in each of the categories: Weeks 1-6, 7-12, 13-18, 19-24, 25-30, 31-36, and 43-48 are reported.

Time frame:
Until PD or end of primary study treatment (up to 16 cycles) plus 28 days.
Reported as:
Number · Percentage of participants
Time to Overall Response
Percentage of participants1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Week 1-62530
Week 7-124830
Week 13-182017
Week 19-2477
Week 25-3031
Week 31-3632
Week 43-4801
SecondaryDuration of Overall Response

Duration of overall response was measured from the time that measurement criteria were first met for Complete Response or Partial Response until the first date that progressive disease or death was documented.

Time frame:
Until PD or death. Median duration of response was approximately 7 months.
Reported as:
Median · Months
Duration of Overall Response
Months1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Duration of Overall Response6.9 (6.1 to 8.6)6.9 (5.8 to 9.0)
SecondaryTime to Treatment Failure

The time to treatment failure was the time from the date of randomization to the first occurrence of any of the following events: * adverse events * insufficient therapeutic response (disease progression) * death * failure to return * refusing treatment/being unwilling to cooperate * withdrawing consent.

Time frame:
Until premature withdrawal or end of primary study treatment (up to 16 cycles).
Reported as:
Median · Months
Time to Treatment Failure
Months1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Time to Treatment Failure5.1 (4.2 to 5.8)4.6 (4.1 to 5.3)
SecondaryOverall Survival

Overall Survival was measured as the time from the date of randomization to the date of death.

Time frame:
Throughout the study. Median observation time was approximately 16 months.
Reported as:
Median · Months
Overall Survival
Months1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Overall Survival16.4 (13.6 to 21.8)15.1 (12.9 to 17.7)
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events

An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is Life-Threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Additional information about Adverse Events can be found in the Adverse Event Section.

Time frame:
First study drug intake until last study drug intake plus 28 days
Reported as:
Number · Participants
Number of Participants With Adverse Events and Serious Adverse Events
Participants1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Adverse Events206234
Serious Adverse Events4153

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1250 mg/m^2 Capecitabine + Docetaxel—41/217 (18.9%)192/217 (88.5%)
825 mg/m^2 Capecitabine + Docetaxel—53/248 (21.4%)223/248 (89.9%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
Event1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Febrile neutropeniaBlood and lymphatic system disorders13/21714/248
NeutropeniaBlood and lymphatic system disorders6/2174/248
Stomatitis allGastrointestinal disorders5/2170/248
Palmar-Plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders3/2171/248
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2173/248
AstheniaGeneral disorders0/2173/248
LeukopeniaBlood and lymphatic system disorders2/2170/248
DiarrhoeaGastrointestinal disorders2/2172/248
VomitingGastrointestinal disorders2/2172/248
Respiratory failureRespiratory, thoracic and mediastinal disorders2/2171/248
Most frequent other events
Showing 10 of 26
Most frequent other events
Event1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + Docetaxel
Palmar-Plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders102/217104/248
Stomatitis allGastrointestinal disorders87/21788/248
NeutropeniaBlood and lymphatic system disorders77/21770/248
AlopeciaSkin and subcutaneous tissue disorders74/21782/248
DiarrhoeaGastrointestinal disorders73/21781/248
FatigueGeneral disorders58/21750/248
NauseaGastrointestinal disorders45/21758/248
VomitingGastrointestinal disorders33/21745/248
PyrexiaGeneral disorders35/21727/248
Nail disorderSkin and subcutaneous tissue disorders26/21738/248

Baseline characteristics

Age Continuous
Age Continuous(years)1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + DocetaxelTotal
Mean50.9 (22 to 75)50.6 (28 to 75)50.75 (22 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)1250 mg/m^2 Capecitabine + Docetaxel825 mg/m^2 Capecitabine + DocetaxelTotal
Female235235470
Male000
08

Study locations

94 sites
  • Birmingham, Alabama 35233, United States
  • Hoover, Alabama 35216, United States
  • Tucson, Arizona 85715, United States
  • Berkeley, California 94704, United States
  • Poway, California 92064, United States
  • Boca Raton, Florida 33486, United States
  • Fort Lauderdale, Florida 33308, United States
  • Inverness, Florida 34452, United States
  • Jacksonville, Florida 32207, United States
  • Miami Shores, Florida 33179, United States
  • Port Saint Lucie, Florida 34952, United States
  • Tamarac, Florida 33321, United States
  • Skokie, Illinois 60076, United States
  • Urbana, Illinois 61801, United States
  • Beech Grove, Indiana 46107, United States
  • Des Moines, Iowa 50314, United States
  • Overland Park, Kansas 66210, United States
  • Houma, Louisiana 70360, United States
  • Baltimore, Maryland 21202, United States
  • Baltimore, Maryland 21236, United States
  • Frederick, Maryland 21701, United States
  • Rockville, Maryland 20850-3348, United States
  • Boston, Massachusetts 02118, United States
  • Detroit, Michigan 48202-2689, United States
  • Kalamazoo, Michigan 49007, United States
  • Jefferson City, Missouri 65109, United States
  • St Joseph, Missouri 64507, United States
  • Paramus, New Jersey 07652, United States
  • Summit, New Jersey 07901, United States
  • Williamsville, New York 14221, United States
  • Canton, Ohio 44718, United States
  • Mayfield Heights, Ohio 44124, United States
  • Allentown, Pennsylvania 18104, United States
  • Kingston, Pennsylvania 18704, United States
  • Charleston, South Carolina 29406, United States
  • Columbia, South Carolina 29203, United States
  • Collierville, Tennessee 38017, United States
  • Knoxville, Tennessee 37920, United States
  • Austin, Texas 78705, United States
  • Houston, Texas 77030, United States
  • Colchester, Vermont 05446, United States
  • Abingdon, Virginia 24211, United States
  • Walla Walla, Washington 99362, United States
  • Mostar, 88000, Bosnia and Herzegovina
  • Sarajevo, 71000, Bosnia and Herzegovina
  • Tuzla, 75000, Bosnia and Herzegovina
  • Beijing, 100021, China
  • Beijing, 100853, China
  • Bengbu, 233004, China
  • Dalian, 116011, China
  • Dalian, 116027, China
  • Hangzhou, 310009, China
  • Shanghai, 200032, China
  • Tianjin, 300060, China
  • Pardubice, 532 03, Czech Republic
  • Praha, 140 59, Czech Republic
  • Praha, 150 06, Czech Republic
  • Praha, 180 00, Czech Republic
  • Tabor, 390 03, Czech Republic
  • Ahmedabad, 380 016, India
  • Bangalore, 560 078, India
  • Bangalore, 560027, India
  • Cochin, 682 026, India
  • Hyderabad, 500 033, India
  • Hyderabad, 500 034, India
  • Hyderabad, 500 082, India
  • Jaipur, 302013, India
  • Kolkata, 700 053, India
  • Ludhiana, 141 001, India
  • Manipal, 576 104, India
  • Mumbai, 400012, India
  • New Delhi, 110085, India
  • Trivandrum, 695 011, India
  • Vellore, 632 004, India
  • Poznan, 61-878, Poland
  • Wroclaw, 50-981, Poland
  • Chelyabinsk, 454087, Russian Federation
  • Ivanovo, 153040, Russian Federation
  • Kazan, 420029, Russian Federation
  • Kazan, 420111, Russian Federation
  • Moscow, 109033, Russian Federation
  • Moscow, 115478, Russian Federation
  • Omsk, 644013, Russian Federation
  • Ryazan, 390046, Russian Federation
  • Samara, 443031, Russian Federation
  • St Petersburg, 197022, Russian Federation
  • St Petersburg, 197758, Russian Federation
  • Yaroslavl, 150054, Russian Federation
  • Bloemfontein, 9301, South Africa
  • Durban, 4001, South Africa
  • Polokwane, 0699, South Africa
  • Bangkok, 10400, Thailand
  • Chiang Mai, 50200, Thailand
  • Khon Kaen, 40002, Thailand
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2004
First posted
Feb 16, 2004
Start
Jul 2003
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
May 10, 2013
Last update
May 10, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00077857
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 16, 2004
Start date
Jul 2003
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
May 10, 2013
Last update
May 10, 2013

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Docetaxel

Start the discussion